SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS) in a report issued on Tuesday, Benzinga reports. They currently have a $6.00 price target on the stock. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q2 2024 earnings at ($1.02) EPS, Q3 2024 earnings at ($1.09) EPS, Q4 2024 earnings at ($1.24) EPS, FY2024 earnings at ($3.89) EPS, FY2025 earnings at ($5.16) EPS and FY2026 earnings at ($5.56) EPS.

Separately, Chardan Capital reaffirmed a buy rating and issued a $25.00 target price on shares of SAB Biotherapeutics in a research report on Tuesday, April 16th.

SAB Biotherapeutics Stock Up 6.2 %

Shares of NASDAQ:SABS opened at $2.75 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.45 and a current ratio of 5.65. SAB Biotherapeutics has a 12 month low of $2.36 and a 12 month high of $10.50. The company’s fifty day simple moving average is $4.20 and its 200 day simple moving average is $3.68.

Hedge Funds Weigh In On SAB Biotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BVF Inc. IL bought a new stake in shares of SAB Biotherapeutics during the fourth quarter worth about $6,310,000. Commodore Capital LP bought a new position in shares of SAB Biotherapeutics during the fourth quarter worth about $1,259,000. RTW Investments LP acquired a new stake in SAB Biotherapeutics during the 4th quarter valued at approximately $6,310,000. Finally, Pathstone Family Office LLC acquired a new position in shares of SAB Biotherapeutics in the 3rd quarter worth approximately $319,000. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.